Daygen L. Finch

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

Matti Annala, Gillian Vandekerkhove, Daniel Khalaf et al. · Cancer Discovery · 2018 · 507 citations · Full text

Pathology, Rapid Resistance, Invasive Biomarkers +17

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

Daniel Khalaf, Matti Annala, Sinja Taavitsainen et al. · The Lancet Oncology · 2019 · 338 citations

Urology, Oncology, Optimal Sequencing +8

Extrapulmonary small cell cancer

Kamal Haider, Rabia Shahid, Daygen L. Finch et al. · Cancer · 2006 · 123 citations · Full text

Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T‐cell lymphoma

Ethan Toumishey, Angeli Prasad, Greg Dueck et al. · Cancer · 2014 · 105 citations · Full text

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Nicolette M. Fonseca, Corinne Maurice‐Dror, Cameron Herberts et al. · Nature Communications · 2024 · 101 citations · Full text